<DOC>
	<DOC>NCT00232297</DOC>
	<brief_summary>Primary objective: - to assess the efficacy of SSR149744C for the prevention of ventricular arrhythmia-triggered ICD interventions. Secondary objectives: - to assess versus placebo the tolerability of the different dose regimens of SSR149744C in the selected population. - to document SSR149744C plasma level during the study.</brief_summary>
	<brief_title>Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS</brief_title>
	<detailed_description />
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Ventricular Fibrillation</mesh_term>
	<mesh_term>Tachycardia, Ventricular</mesh_term>
	<criteria>Patient with an ICD implanted during the previous year for documented spontaneous lifethreatening ventricular arrhythmia OR implanted with an ICD and with at least one appropriate ICD therapy (shock or antitachycardia pacing) for ventricular tachycardia or ventricular fibrillation in the previous year. Left ventricular ejection fraction measured by 2Dechocardiography must have been documented to be less than 40% in the last 6 months. MAIN CRITERIA (nonexhaustive list): Women of childbearing potential without adequate birthcontrol, Pregnant Women, Breastfeeding women, conditions which increase the risk of severe antiarrhythmic drug side effects, severe associated conditions.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tachycardia, Ventricular</keyword>
	<keyword>Ventricular Fibrillation</keyword>
	<keyword>Defibrillators Implantable</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Anti-arrhythmia agents</keyword>
</DOC>